bluebird reports updated Phase I bb2121 data

bluebird bio Inc. (NASDAQ:BLUE) reported updated data from the Phase I CRB-401 trial evaluating its CAR T cell therapy bb2121 in patients with relapsed or refractory multiple myeloma. The data were

Read the full 312 word article

User Sign In